Greenspring Advisors LLC Buys 250 Shares of Eli Lilly and Company (NYSE:LLY)

Greenspring Advisors LLC raised its stake in shares of Eli Lilly and Company (NYSE:LLY) by 20.2% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,490 shares of the company’s stock after acquiring an additional 250 shares during the quarter. Greenspring Advisors LLC’s holdings in Eli Lilly and Company were worth $1,231,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Garner Asset Management Corp increased its holdings in Eli Lilly and Company by 2.3% in the 4th quarter. Garner Asset Management Corp now owns 532 shares of the company’s stock worth $411,000 after purchasing an additional 12 shares in the last quarter. FWG Holdings LLC increased its holdings in Eli Lilly and Company by 0.6% in the 4th quarter. FWG Holdings LLC now owns 2,023 shares of the company’s stock worth $1,640,000 after purchasing an additional 12 shares in the last quarter. Morling Financial Advisors LLC increased its holdings in Eli Lilly and Company by 4.7% in the 4th quarter. Morling Financial Advisors LLC now owns 266 shares of the company’s stock worth $205,000 after purchasing an additional 12 shares in the last quarter. Prestige Wealth Management Group LLC increased its holdings in Eli Lilly and Company by 2.0% in the 4th quarter. Prestige Wealth Management Group LLC now owns 606 shares of the company’s stock worth $468,000 after purchasing an additional 12 shares in the last quarter. Finally, Applied Finance Capital Management LLC increased its holdings in Eli Lilly and Company by 1.4% in the 4th quarter. Applied Finance Capital Management LLC now owns 855 shares of the company’s stock worth $660,000 after purchasing an additional 12 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Trading Up 0.6%

NYSE LLY opened at $770.00 on Friday. The business has a 50 day simple moving average of $770.87 and a 200 day simple moving average of $800.27. Eli Lilly and Company has a one year low of $677.09 and a one year high of $972.53. The stock has a market capitalization of $729.76 billion, a P/E ratio of 65.76, a P/E/G ratio of 1.40 and a beta of 0.40. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The business had revenue of $12.73 billion for the quarter, compared to analyst estimates of $12.77 billion. During the same period in the prior year, the business earned $2.58 EPS. The company’s revenue for the quarter was up 45.2% on a year-over-year basis. Research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th will be paid a $1.50 dividend. The ex-dividend date is Friday, May 16th. This represents a $6.00 dividend on an annualized basis and a yield of 0.78%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 48.82%.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the sale, the chief accounting officer now owns 5,840 shares of the company’s stock, valued at approximately $4,778,521.60. This trade represents a 14.62% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.13% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on LLY shares. Erste Group Bank downgraded Eli Lilly and Company from a “buy” rating to a “hold” rating in a research report on Thursday. UBS Group lowered their price objective on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a “buy” rating for the company in a research report on Friday, May 2nd. The Goldman Sachs Group upgraded Eli Lilly and Company from a “neutral” rating to a “buy” rating and lowered their price objective for the stock from $892.00 to $888.00 in a research report on Tuesday, April 8th. Wells Fargo & Company restated an “overweight” rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Finally, Cantor Fitzgerald started coverage on Eli Lilly and Company in a research report on Tuesday, April 22nd. They set an “overweight” rating and a $975.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and eighteen have issued a buy rating to the stock. According to data from MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus price target of $1,011.37.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.